New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Carlisle (CSL) PT Raised to $118 at Baird Following Solid 3Q

October 25, 2017 9:05 AM EDT

Baird raised its price target on Carlisle (NYSE: CSL) to $118.00 (from $110.00) while maintaining a Outperform rating following the company's 3Q earnings report. CSL's Q3 results exceeded recently lowered expectations. EPS of $1.37, exceeding consensus' $1.35 estimate. Revenune of $1,089m was also higher than consensus ($1,049m).

CSL now... More